Get the Stockscreener App
0.945
0.52%
0.025
Io Biotech Inc stock is traded at $0.945, with a volume of 35,514.
It is up +0.52% in the last 24 hours and up +8.33% over the past month.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$0.97
Open:
$0.9315
24h Volume:
35,514
Relative Volume:
0.10
Market Cap:
$63.90M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.438
EPS:
-2.1574
Net Cash Flow:
$-72.06M
1W Performance:
+8.33%
1M Performance:
+8.33%
6M Performance:
-26.14%
1Y Performance:
-45.53%
1-Day Range:
$0.93
$0.98
1-Week Range:
$0.8626
$0.98
52-Week Range:
$0.66
$1.89
Io Biotech Inc Stock (IOBT) Company Profile
Name
Io Biotech Inc
Sector
Industry
Phone
(457) 070-2980
Address
OLE MAALOES VEH 3, COPENHAGEN
Compare IOBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.945 | 63.90M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.56 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.92 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.42 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.81 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.98 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Io Biotech Inc Stock (IOBT) Latest News
Clinical Trials News Live Feed - StockTitan
IO Biotech advances cancer vaccine candidate IO112 - MSN
IO Biotech advances cancer vaccine candidate IO112 By Investing.com - Investing.com Canada
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate - The Manila Times
Hill International Providing Program Management and Oversight Services to Support the Port of Oakland's Capital Improvement Program - The Manila Times
Revolutionary Cancer Vaccine IO112 Transforms Tumor Environment, New Study Reveals Major Breakthrough - StockTitan
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Down 68.6% in January - MarketBeat
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - Yahoo Finance
Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - Morningstar
Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - Yahoo Finance
Small-Cap Miner Rallies On Exclusive Offtake Agreement - The Globe and Mail
Melanoma FDA Approvals, Pipeline Insights, Clinical Trials Assessment and Companies | DelveInsight - openPR
Jefferies maintains IO Biotech Buy rating, $8 target on PFS hopes - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy - MSN
Non-small Cell Lung Cancer Clinical and Non-Clinical Studies, - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short Interest - MarketBeat
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor - Healio
IO Biotech Completes Enrollment in Its Neoadjuvant/Adjuvant Phase 2 Basket Trial (IOB-032/PN-E40) - Marketscreener.com
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer - The Manila Times
IO Biotech Fast-Tracks Cancer Vaccine Trial, Completes Phase 2 Enrollment Early - StockTitan
5 Best Microbiome Companies (January 2025) - Securities.io
IO Biotech faces possible Nasdaq delisting over low stock price By Investing.com - Investing.com Australia
IO Biotech faces possible Nasdaq delisting over low stock price - Investing.com India
IO Biotech Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement - Defense World
IO Biotech's chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Australia
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 210.5% in December - MarketBeat
IO Biotech’s chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Nigeria
IO Biotech's chief medical officer acquires $26,553 in common stock - Investing.com
Io biotech general counsel Devin Smith acquires $9,720 in shares By Investing.com - Investing.com Nigeria
IO Biotech CEO Mai-Britt Zocca acquires $10,120 in company stock - Investing.com India
IO Biotech (NASDAQ:IOBT) Adopts Amended and Restated Bylaws - Defense World
Io biotech general counsel Devin Smith acquires $9,720 in shares - Investing.com India
IO Biotech CFO Amy Sullivan buys $8,482 in common stock By Investing.com - Investing.com Nigeria
IO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in Stock - MarketBeat
IO Biotech CFO Amy Sullivan buys $8,482 in common stock - Investing.com
IO Biotech Secures €57.5 Million Debt Financing from European Investment Bank - Defense World
IO Biotech announces up to €57.5M debt financing from the European Investment Bank - MSN
IO Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank - citybiz
IO Biotech secures €57.5 million EIB loan for cancer vaccines By Investing.com - Investing.com Canada
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Marketscreener.com
IO Biotech Secures €57.5M EIB Loan Facility to Advance Cancer Vaccine Development Pipeline - StockTitan
IO Biotech (NASDAQ:IOBT) Trading Down 1.3%Here's Why - MarketBeat
IO Biotech (NASDAQ:IOBT) Shares Down 1.3% – Here’s What Happened - Defense World
IO Biotech amends bylaws and adjusts fiscal year-end - Investing.com
IO Biotech : Amendments to Bylaws Form 8 K - Marketscreener.com
Io Biotech Inc Stock (IOBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Io Biotech Inc Stock (IOBT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zocca Mai-Britt | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.81 |
12,500 |
10,120 |
49,891 |
| Sullivan Amy | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.83 |
10,250 |
8,483 |
84,632 |
| Smith Devin Whittemore | General Counsel |
Dec 23 '24 |
Buy |
0.81 |
12,000 |
9,720 |
16,938 |
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):